Assignee
TRILLIUM THERAPEUTICS INC
CA·25 granted patents·16 pending applications·449 citations·filing 2000–2020
Top patents by PatentIndex Score
41 records- 0197US7238352B2Methods and compositions for modulating tumor growthTRILLIUM THERAPEUTICS INC·Filed 2005·Granted Jul 3, 2007·43 cites·5 claims
- 0296US7887798B2Methods of treating cancer by administering antibodies to CD200TRILLIUM THERAPEUTICS INC·Filed 2008·Granted Feb 15, 2011·20 cites·12 claims
- 0396US6955811B2Methods of inhibiting immune response suppression by administering antibodies to OX-2TRILLIUM THERAPEUTICS INC·Filed 2001·Granted Oct 18, 2005·51 cites·9 claims
- 0495US7452536B2Methods of treating cancer by administering antibodies to CD200TRILLIUM THERAPEUTICS INC·Filed 2007·Granted Nov 18, 2008·23 cites·19 claims
- 0594US7902151B2Methods and compositions for modulating immunityTRILLIUM THERAPEUTICS INC·Filed 2009·Granted Mar 8, 2011·19 cites·15 claims
- 0693US6984625B2Methods and compositions for modulating autoimmunityTRILLIUM THERAPEUTICS INC·Filed 2001·Granted Jan 10, 2006·40 cites·14 claims
- 0793US6749854B2Use of OX-2 to inhibit fetal lossTRILLIUM THERAPEUTICS INC·Filed 2001·Granted Jun 15, 2004·41 cites·12 claims
- 0893US6652858B2Use of OX-2 to suppress an immune responseTRILLIUM THERAPEUTICS INC·Filed 2001·Granted Nov 25, 2003·39 cites·13 claims
- 0990US10906954B2Treatment of CD47+ disease cells with SIRPα-Fc fusionsTRILLIUM THERAPEUTICS INC·Filed 2018·Granted Feb 2, 2021·11 cites·14 claims
- 1090US9969789B2Treatment of CD47+ disease cells with SIRP alpha-Fc fusionsTRILLIUM THERAPEUTICS INC·Filed 2013·Granted May 15, 2018·33 cites·4 claims
- 1188US7368535B2CD200 receptorsTRILLIUM THERAPEUTICS INC·Filed 2002·Granted May 6, 2008·39 cites·10 claims
- 1287US7332631B2Fc receptor modulating compounds and compositionsTRILLIUM THERAPEUTICS INC·Filed 2003·Granted Feb 19, 2008·38 cites·4 claims
- 1383US10259809B2Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteinsTRILLIUM THERAPEUTICS INC·Filed 2016·Granted Apr 16, 2019·2 cites·24 claims
- 1479US7223729B2Methods of treating allergy by administering a CD200 proteinTRILLIUM THERAPEUTICS INC·Filed 2004·Granted May 29, 2007·4 cites·7 claims
- 1578US7205386B2Truncated CD200TRILLIUM THERAPEUTICS INC·Filed 2001·Granted Apr 17, 2007·10 cites·6 claims
- 1673US7351875B2FcγRIIa transgenic animal model for autoimmune diseaseTRILLIUM THERAPEUTICS INC·Filed 2003·Granted Apr 1, 2008·20 cites·8 claims
- 1773US6642433B1Fgl-2 knockout miceTRILLIUM THERAPEUTICS INC·Filed 2000·Granted Nov 4, 2003·8 cites·12 claims
- 1868US7291330B2MD-1 inhibitors as immune suppressantsTRILLIUM THERAPEUTICS INC·Filed 2001·Granted Nov 6, 2007·3 cites·3 claims
- 1968US6805863B2Methods of modulating immune coagulationTRILLIUM THERAPEUTICS INC·Filed 2001·Granted Oct 19, 2004·3 cites·3 claims
- 2064US10696670B2Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteinsTRILLIUM THERAPEUTICS INC·Filed 2019·Granted Jun 30, 2020·0 cites·18 claims
- 2164US10604476B2Fluorinated amide derivatives and their uses as therapeutic agentsTRILLIUM THERAPEUTICS INC·Filed 2016·Granted Mar 31, 2020·0 cites·14 claims
- 2262US7553811B2Methods and compositions for modulating immunityTRILLIUM THERAPEUTICS INC·Filed 2007·Granted Jun 30, 2009·0 cites·2 claims
- 2361US2019367466A1Heterocycle derivatives and their use for the treatment of cns disordersTRILLIUM THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2460US7910770B2Fc receptor modulating compounds and compositionsTRILLIUM THERAPEUTICS INC·Filed 2008·Granted Mar 22, 2011·0 cites·14 claims
- 2560US2021206829A1Treatment of cd47+ disease cells with sirp alpha-fc fusionsTRILLIUM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2659US2005169913A1Compositions comprising antibodies to human FgI2TRILLIUM THERAPEUTICS INC·Filed 2004·Application pending·0 cites
- 2758US7196243B2Transgenic animal containing CD200 and uses thereforTRILLIUM THERAPEUTICS INC·Filed 2003·Granted Mar 27, 2007·2 cites·9 claims
- 2857US2011206668A1Methods and compositions for modulating immunityTRILLIUM THERAPEUTICS INC·Filed 2011·Application pending·0 cites
- 2953US2021040224A1Cd47 blockade therapy with cd38 antibodyTRILLIUM THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3053US2020181067A1Fluorinated amide derivatives and their uses as therapeutic agentsTRILLIUM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3152US10428030B2Heterocycle derivatives and their use for the treatment of CNS disordersTRILLIUM THERAPEUTICS INC·Filed 2016·Granted Oct 1, 2019·0 cites·17 claims
- 3249US2005042226A1Treatment of chronic human viral hepatitisTRILLIUM THERAPEUTICS INC·Filed 2004·Application pending·0 cites
- 3344US2021040219A1Improvements in cd47 blockade therapy by egfr antibodyTRILLIUM THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3444US2016347792A1Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitorsTRILLIUM THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3539US2020157179A1Cd47 blockade therapyTRILLIUM THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3639US2022289821A1Biomarkers for cd47 blockade therapyTRILLIUM THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3738US2019016689A1Novel fluorinated quinazoline derivatives as egfr inhibitorsTRILLIUM THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3837US2020031825A1Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonistsTRILLIUM THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3937US2019091290A1Macrophage stimulation in cd47 blockade therapyTRILLIUM THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4036US2018050993A1Novel fluorinated derivatives as egfr inhibitors useful for treating cancersTRILLIUM THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4135US2018016227A1Process for the synthesis of difluoromethyl ether-based compoundsTRILLIUM THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when TRILLIUM THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →